Literature DB >> 3942847

Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression.

P T Dawes, P D Fowler, S Clarke, J Fisher, A Lawton, M F Shadforth.   

Abstract

One hundred and fifty consecutive patients with active, rheumatoid arthritis were assessed and treated with gold, D-penicillamine, chloroquine or dapsone. Four groups were selected from these patients. Group I consisted of 60 patients who did not complete 12 months' therapy. Group II consisted of patients in whom ESR and C-reactive protein (CRP) fell to less than 30 mm/h and less than 20 mg/l, respectively, and remained at these levels between 6 and 12 months. In group IV the ESR and CRP fell but remained greater than 30 and greater than 20, respectively, during the same period. Group III patients had variable ESRs and CRPs between 6 and 12 months. In groups II, III and IV there was a significant deterioration (p less than 0.01) in the hand and foot radiographs from 0 to 6 months. Between 6 and 12 months the radiographs in groups III and IV continued to show significant radiological progression (p less than 0.01), but those of group II did not alter. These results suggest radiological deterioration continues during the first 6 months regardless of clinical response but thereafter, further deterioration is less likely to occur when the ESR and CRP are consistently controlled.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3942847     DOI: 10.1093/rheumatology/25.1.44

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  30 in total

1.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

3.  Anti-inflammatory and anti-arthritic effects of 3-hydroxy, 2-methoxy sodium butanoate from the leaves of Clerodendrum phlomidis L.f.

Authors:  N Prakash Babu; S Saravanan; P Pandikumar; K Bala Krishna; M Karunai Raj; S Ignacimuthu
Journal:  Inflamm Res       Date:  2013-11-08       Impact factor: 4.575

4.  Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.

Authors:  P F Moore; D L Larson; I G Otterness; A Weissman; S B Kadin; F J Sweeney; J D Eskra; A Nagahisa; M Sakakibara; T J Carty
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

5.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects.

Authors:  M J Gardner; K D Wilner; R A Hansen; H G Fouda; G F McMahon
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

Review 7.  Tenidap: not just another NSAID?

Authors:  J M Canvin; R Madhok
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

8.  Phenytoin in rheumatoid arthritis.

Authors:  K A Grindulis; F E Nichol; R Oldham
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

9.  Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy.

Authors:  P T Dawes; P D Fowler; R Jackson; M Collins; M F Shadforth; R Stone; D L Scott
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

10.  Precision of Larsen grading of radiographs in assessing progression of rheumatoid arthritis in individual patients.

Authors:  M M O'Sullivan; P A Lewis; R G Newcombe; N J Broderick; D A Robinson; E C Coles; J D Jessop
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.